Researchers at The University of Texas MD Anderson Cancer Center have identified a specific protein, RASH3D19, that is ...
Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with ...
Morning Overview on MSN
Key lifestyle link emerges in major pancreatic cancer find
Pancreatic cancer has long been one of the deadliest malignancies in medicine, largely because it is usually detected late and resists many standard treatments. A growing body of research is now ...
An aggressive breast cancer lacking common drug targets, triple-negative breast cancer may be countered by oridonin, a ...
Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality ...
Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...
In several disease conditions, including infections and cancers, innate immune activation and nutrient scarcity occur together.
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...
After a finite number of divisions, cells simply give up. As each round of replication trims their telomeres—the protective ...
Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...
In several disease conditions, including infections and cancers, innate immune activation and nutrient scarcity occur ...
A TOR-targeting cancer drug unexpectedly extends yeast lifespan through a newly discovered metabolic feedback loop.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback